11/10/2005 1:49:23 PM ET


    SWISS MEDICA ANNOUNCES THE LAUNCH OF THE NATIONAL FIBROMYALGIA ASSOCIATION’S AWARENESS
    CAMPAIGN FOR O24 FIBROMYALGIA™
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    November 10, 2005

    SWISS MEDICA ANNOUNCES THE LAUNCH OF THE NATIONAL FIBROMYALGIA ASSOCIATION’S AWARENESS
    CAMPAIGN FOR O24 FIBROMYALGIA™

    Toronto, Canada - Swiss Medica, Inc. (OTCBB: SWME) today announced the launch of a national awareness
    program by the National Fibromyalgia Association (NFA) for the Company’s new patented, clinically tested O24
    Fibromyalgia™ product which is now available in over 5,000 retail outlets in the United States. In part, this
    nationwide program announces the granting of the NFA’s first ever Seal of Approval to O24 Fibromyalgia™.

    The national NFA campaign includes:

  • A news letter noting the NFA Seal of Approval for O24 Fibromyalgia™ will be sent this week to tens of thousands
    of people in the Fibromyalgia community.

  • The NFA will also be profiled in Parade Magazine on Sunday November 13. Parade is a national weekly
    publication with a circulation of 34,500,000.

  • An email alert to tens of thousands Fibromyalgia sufferers across the United States on announcing which
    retailers are carrying O24 Fibromyalgia™.

  • An editorial product profile on O24 Fibromyalgia™ will appear in the December edition of the NFA’s monthly
    magazine, Fibromyalgia Aware, a paid circulation publication received by more that 50,000 subscribers. The
    Fibromyalgia Aware magazine will also include two samples of O24 Fibromyalgia™ in each copy.

  • A distribution of 40,000 O24 Fibromyalgia™ product samples to more than 1,650 Fibromyalgia support groups
    across the United States during the first week of December.

  • The mailing of samples of O24 Fibromyalgia™, and a letter from the National Fibromyalgia Association detailing
    the NFA Seal of Approval and the other attributes of the clinically tested O24 Fibromyalgia™ to more than 6,000
    primary care physicians in the United States specializing in the diagnosis and treatment of Fibromyalgia.

    It is anticipated that this NFA-led campaign will touch millions of people in the next two months.

    O24 Fibromyalgia™ is the only focused Fibromyalgia product available in national retailers to specifically
    address the pain associated with the Fibromyalgia condition. US Patented O24 Fibromyalgia™ has been
    clinically-tested in a randomized double blind study and its effectiveness for Fibromyalgia pain was clinically
    shown to be very conclusive.

    In assessing this aggressive marketing push to support the recent launch of O24 Fibromyalgia™, Swiss Medica’s
    President and Chief Operating Officer, Grant Johnson says, “These activities are indicative of the strategic
    moves the Company is making to align our various products with core users and leverage key influencers for
    chronic ailment solutions.”

    About Swiss Medica, Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a
    world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
    throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
    www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

    Swiss Medica is launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1) over-the-
    counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently
    awarded O24 Fibromyalgia™ their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the
    long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of
    the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
    who used the placebo. Customers can visit www.O24zone.com for information on O24 Fibromyalgia™ and to
    order the product online.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
    www.pmsescape.com for additional information and ordering details.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact:

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    djones@swissmedica.com